MedTrace Logo

An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)

NCT01811186 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 261

Last updated 2017-03-10

Study results available
· View outcomes & findings →

Summary

Objectives:

1. Objective of main interest

\- To assess the drop-out rate caused by adverse event\* after 6 weeks treatment
2. Further objectives

* To assess the drop-out rate caused by adverse event\* after 1 week treatment
* To assess the pain reduction rate after 6 weeks treatment from baseline
* To assess the Euroquol (EQ-5D) quality of life
* To assess physician's overall satisfaction
* To assess subject's overall satisfaction
* To assess safety

Conditions

Interventions

DRUG

Oxycodone/naloxone

Oxycodone/naloxone titration

Sponsors & Collaborators

  • Mundipharma Korea Ltd

    lead INDUSTRY

Principal Investigators

  • Hoseong Lee, Dr. · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-01-31
Completion
2014-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01811186 on ClinicalTrials.gov